The stock market gave back a bit of its October rally Tuesday, but certainly not enough to derail it. The Nasdaq lost 0.5%, as renewed selling in biotechs and other Nasdaq-residing medicals dragged the composite. Valeant Pharmaceuticals (VRX) said at its earnings announcement late Monday that controversy over high drug prices is leading the company to consider new strategies. Investors no doubt took it as a bad sign for industry profits.